
Home
Chapter Home
Jobs
Conferences
Fellowships
Books
Advertisement
Prostate
Miscellaneous
Staging
Reviewers: Komal Arora, M.D., (see Reviewers page)
Revised: 29 July 2012, last major update July 2012
Copyright: (c) 2003-2012, PathologyOutlines.com, Inc.
General
=========================================================================
References: AJCC Cancer Staging Manual (7th ed), staging forms, National Cancer Institute (US)
Primary tumor (T) - Clinical staging
● TX: Primary tumor cannot be assessed
● T0: No evidence of primary tumor
● T1: Clinically inapparent tumor neither palpable nor visible by imaging
● T1a: Tumor incidental histologic finding in 5% or less of tissue resected
● T1b: Tumor incidental histologic finding in more than 5% of tissue resected
● T1c: Tumor identified by needle biopsy (e.g. because of elevated PSA)
● T2: Tumor confined within prostate
● T2a: Tumor involves one half of one lobe or less
● T2b: Tumor involves more than one half of one lobe, but not both lobes
● T2c: Tumor involves both lobes
● T3: Tumor extends through the prostatic capsule
● T3a: Extracapsular extension (unilateral or bilateral)
● T3b: Tumor invades seminal vesicle(s)
● T4: Tumor is fixed or invades adjacent structures other than seminal vesicles such as external sphincter, rectum, bladder, levator muscles or pelvic wall
Notes:
● Tumor found in one or both lobes by needle biopsy, but not palpable or reliably visible by imaging, is classified as T1c
● Invasion into the prostatic apex or into (but not beyond) the prostatic capsule is classified as T2, not T3
Primary tumor (T) - Pathologic staging
● pT2: Organ confined
● pT2a: Unilateral, one half of one side or less
● pT2b: Unilateral, involving more than one half of one side, but not both sides
● pT2c: Bilateral disease
● pT3: Extraprostatic extension
● pT3a: Extraprostatic extension or microscopic invasion of bladder neck
● pT3b: Seminal vesicle invasion
● pT4: Invasion of rectum, levator muscles or pelvic wall
Notes:
● Tumor found in one or both lobes by needle biopsy, but not palpable or reliably visible by imaging, is classified as T1c
● Invasion into the prostatic apex or into (but not beyond) the prostatic capsule is classified as T2, not T3
● There is no pathologic T1 classification
● Value of T2 substaging has been questioned (J Urol 2011;186:790)
● Margins are important, and margin status is independent of T classification; classify positive margins as either focal or extensive based on the length of involvement of the inked line of resection
● Laterality of extraprostatic extension (EPE) is not prognostically important
● EPE should be quantitated as focal (< 1 HPF on 1-2 sections) or nonfocal
● Determine EPE in radical prostatectomy specimens by comparing the presence of tumor to the normal edge of the prostate gland
● Seminal vesicle invasion means tumor invades its muscular coat, seen first at the base of the seminal vesicles
● The amount of tumor in the seminal vesicles is not important
● pT3 can have positive or negative margins
● Patients with clinical T3 disease are usually not surgical candidates - 50% have nodal metastases at diagnosis, 50% develop metastases at 5 years and 75% die of prostate carcinoma within 10 years
● Margins: apex is most frequent site of positive margin; positive margins at base usually indicate extensive disease; tumor at anterior region margin usually is considered extraprostatic extension because usually is exterior to prostate; Close margins (< 1 mm) are considered adequate for prostate
Regional lymph nodes (N)
● NX: Regional lymph nodes were not assessed
● N0: No regional lymph node metastasis
● N1: Metastasis in regional lymph node(s)
Notes:
● pNX, pN0 and pN1 are the same as cNX, cN0 and cN1
● NX, N0, N1 may lack clinical relevance; Some surgeons proceed with radical prostatectomy even if nodes are positive at frozen section if preoperative Gleason score is 7 or less, since time to onset of distant metastases is long
● Metastases to periprostatic or periseminal vesicle lymph nodes suggests poor prognosis (Am J Surg Pathol 2001;25:1429)
Distant metastases
● M0: No distant metastasis
● M1: Distant metastasis
● M1a: Distant metastasis to non-regional lymph node(s)
● M1b: Distant metastasis to bone(s)
● M1c: Distant metastasis to other site(s) with or without bone disease
Notes:
● When more than one site of metastasis is present, the most advanced category is used
● pM1c is most advanced
Anatomic stage / Prognostic groups
● Stage I: T1a-2a N0 M0 PSA<10 Gleason 6 or less OR T1-2a N0 M0 PSA unknown Gleason unknown
● Stage IIA: T1a-c N0 M0 PSA < 20 Gleason 7 OR T1a-c N0 M0 PSA 10-19.9 Gleason 6 or less OR
T2a-b N0 M0 PSA < 20 Gleason 7 or less OR T2b N0 M0 PSA unknown Gleason unknown
● Stage IIB: T2c N0 M0 Any PSA Any Gleason OR T1-2 N0 M0 PSA 20 or higher Any Gleason OR
T1-2 N0 M0 Any PSA Gleason 8 or higher
● Stage III: T3a-b N0 M0 Any PSA Any Gleason score
● Stage IV: T4 or N1 or M1
Notes:
● When either PSA or Gleason is not available, grouping should be determined by T stage or either PSA or Gleason as available
● Partin tables: Nomograms predicting pathologic stage based on TNM clinical stage, PSA and Gleason score (Johns Hopkins, J Urol 1993;150:110)
● Close relationship between pathologist and urologist is essential (European Urology Supplements 2008;7:1)
Diagrams
=========================================================================
Micro images
=========================================================================
Extraprostatic extension
Radical prostatectomy with periprostatic fat tissue invasion (pT3a): left - direct invasion, right - invasion through neurovascular bundle
Radical prostatectomy with periprostatic fat tissue invasion (pT3a): adenocarcinoma is outside the edge of the extraprostatic area (discontinuous line) at the level of periprostatic fat tissue (arrows)
End of Prostate > Miscellaneous > Staging
This information is intended for physicians and related personnel, who understand that medical information is often imperfect, and must be interpreted in the context of a patient's clinical data using reasonable medical judgment. This website should not be used as a substitute for the advice of a licensed physician.
All information on this website is protected by copyright of PathologyOutlines.com, Inc. Information from third parties may also be protected by copyright. Please contact us at copyrightPathOut@gmail.com
with any questions (click here for other
contact information).